Robert C Baxter

ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 7

Top Topics

Binding Protein

Amyotrophic Lateral Sclerosis

Mesenchymal Stem Cells

Top Venues

Nature reviews. Endocrinology

Cellular and molecular life sciences : CMLS

Scientific reports

University of Sydney

University of Sydney (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

University of Sydney Feb 07 2019

Australia

Emeritus Professor :: Kolling Institute, Northern Clinical School

University of Sydney Jan 14 1994 - Dec 31 2018

Australia

Professor :: Kolling Institute of Medical Research

Royal Prince Alfred Hospital Jan 01 1975 - Jan 13 1994

Australia

Hospital Scientist :: Endocrinology

Education History

University of Sydney Jan 01 1968 - Sep 30 1971

Australia

PHD :: Biochemistry

Publications

Robert C Baxter
Endocrine and cellular physiology and pathology of the insulin-like growth factor acid-labile subunit. Nature reviews. Endocrinology (2024)
Robert C Baxter
Endocrine and cellular physiology and pathology of the insulin-like growth factor acid-labile subunit. Nature reviews. Endocrinology 20 (7) (2024)
Robert C Baxter
Endocrine and cellular physiology and pathology of the insulin-like growth factor acid-labile subunit. Nature reviews. Endocrinology 20 (7) (2024)
Robert C Baxter
Signaling Pathways of the Insulin-like Growth Factor Binding Proteins. Endocrine reviews (2023)
Aidan Kerr, Robert C Baxter
Noncoding RNA actions through IGFs and IGF binding proteins in cancer. Oncogene 41 (25) (2022)
Hasanthi C de Silva, Mike Z Lin, Leo Phillips, Janet L Martin, Robert C Baxter
IGFBP-3 interacts with NONO and SFPQ in PARP-dependent DNA damage repair in triple-negative breast cancer. Cellular and molecular life sciences : CMLS 76 (10) (2019)
Wendy Ha, Hatice Sevim-Nalkiran, Ashraf M Zaman, Kazuko Matsuda, Mustafa Khasraw, Anna K Nowak, Liping Chung, Robert C Baxter, Kerrie L McDonald
Ibudilast sensitizes glioblastoma to temozolomide by targeting Macrophage Migration Inhibitory Factor (MIF). Scientific reports 9 (1) (2019)